Dry Eye Syndrome Treatment Market Size, Share, Analysis 2031

Segments - Dry Eye Syndrome Treatment Market by Types (Evaporative Dry Eye Syndrome and Aqueous Dry Eye Syndrome), Treatments (Cyclosporine, Corticosteroids, Artificial Tears, and Punctual Bags), Distribution Channels (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

Dry Eye Syndrome Treatment Market Outlook 2031:

The global dry eye syndrome treatment market size was valued at USD 4.81 Billion in 2022 and is projected to reach USD 8.41 Billion by 2031, expanding at a CAGR of 6.4% during the forecast period 2023 - 2031. The growth of the market is attributed to the increasing geriatric population and rising cases of dry eye issues such as conjunctivitis.

Dry eye syndrome, shortly known as conjunctivitis, is a disorder related to the dryness of fluid that lubricates the eyes. This can be caused by various conditions such as low fluid or fast evaporation of tear present around the film on the eyes’ surface. At first, the symptoms of dry eye illness are similar to those of other eye-related diseases such as itching, burning, heavy eyes, red eyes, aching eyes, and blurred vision.

This disorder is considered to be one of the most prevailed eye-related problems and is widely occurred among the aging population globally. A major cause of dry eye syndrome among the aging population is due to rapid decrease in tear production due to weakening of eye muscles of this group. Additionally, those people who are constantly using contact lens due to several eye-related disorders are likely to have a higher chance of developing this syndrome.

According to a poll conducted by Shire plc, women over the age of 50 are more likely to suffer from dry eye illness. Furthermore, rising healthcare expenditure from governments and awareness about the disease's diagnosis and treatment among people present key factors driving the market expansion.

Under the direction of Shire plc, the National Eye C.A.R.E (Current Attitudes Related to Eye Health) conducted an online study of about 1,000 eye care professionals in 2015 to access the number of patients among the adult population.

Spending long hours using tablet, smartphone, and computer are likely to cause eye strain and may result in the onset of eye-related issues. Moreover, factors related to environmental variables, and autoimmune illnesses with systemic drugs are also responsible for this syndrome.

Dry Eye Syndrome Treatment Market Trends, Drivers, Restraints, and Opportunities

Increasing geriatric population and rising use of contact lens among the young population globally is expected to boost the market growth during the forecast period.
Growing awareness about advanced treatment and diagnosis of the disease is anticipated to spur the market expansion in the coming years.
Availability of a wide range of treatment alternatives for dry eye disease, such as lubricating eye drops, punctual bags, artificial tears, and medicines, is projected to propel the market.
Rising healthcare expenditure and several governments’ awareness programs for eye-related issues are projected to propel the market growth during the forecast period.
Lack of skilled ophthalmologists is estimated to impede the market expansion during the forecast period.

Scope of the Dry Eye Syndrome Treatment Market Report

The report on the global dry eye syndrome treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Dry Eye Syndrome Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Types (Evaporative Dry Eye Syndrome and Aqueous Dry Eye Syndrome), Treatments (Cyclosporine, Corticosteroids, Artificial Tears, and Punctual Bags) and Distribution Channels (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Novartis AG (Alcon); ALLERGAN; Johnson & Johnson Vision Care, Inc.; Otsuka Pharmaceutical Vo. Ltd.; Shire plc; OASIS Medical; Santen Pharmaceutical Co. Ltd.; AFT Pharmaceuticals; I-Med Pharma Inc.; Novaliq GmbH; Sentiss Pharma Pvt. Ltd.; and Scope Ophthalmics Ltd.

Dry Eye Syndrome Treatment Market Segment Insights

Aqueous dry eye syndrome segment is expected to grow at a rapid pace

Based on types, the global dry eye syndrome treatment market is bifurcated into evaporative dry eye syndrome and aqueous dry eye syndrome. The aqueous dry eye syndrome segment is expected to grow at a rapid pace during the forecast period owing to rapid development of technology for the treatment of the disorder type.

Santen Pharmaceutical Co., Ltd. and Oxford Biomedica signed an R&D partnership agreement as well as an Option and License agreement in June 2019 to advance gene therapy vectors for inherited retinal illnesses. The partnership deal was to generate pre-clinical proof of concept for treating inherited retinal illnesses with OXB's lentiviral vectors.

Corticosteroid segment is projected to hold a key market share

On the basis of treatments, the market is divided into cyclosporine, corticosteroids, artificial tears, and punctual bags. The corticosteroids segment is expected to account for a key share of the market during the forecast period. Corticosteroids are anti-inflammatory medications widely adopted for the disease treatment especially for acute cases of dry eye disease because of their great short-term efficacy.

These medications are frequently prescribed by doctors and medical practitioners in conjunction with antibiotic therapy. Other factors expected to push the segment growth include increasing product approvals and new product launches related to the treatment type. For example, the US Food and Drug Administration authorized loteprednol etabonate ophthalmic suspension 0.25 percent in 2020 for the short-term treatment of dry eye disease signs and symptoms.

Online pharmacies segment is anticipated to register a substantial CAGR

In terms of distribution channels, the dry eye syndrome treatment market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. The online pharmacy segment is anticipated to register a substantial CAGR during the forecast period owing to rising preference to buy medicines and drugs from online pharmacy. These online stores provide fast delivery service and offer heavy discounts on buying medications, which draw the attention of a large number of costumers.

Dry Eye Syndrome Treatment Market Distribution channel

North America is anticipated to dominate the market

On the basis of regions, the dry eye syndrome treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period owing to the presence of several key global players and wide awareness about the availability of advanced diagnostic and treatment centers in the region.

Moreover, factors such as early adoption of innovative technology among players and increasing use of computer or digital screens to ensure easy and convenient diagnostic process for the patients are expected to push the regional market growth.

Dry Eye Syndrome Treatment Market Region

Segments

The global dry eye syndrome treatment market has been segmented on the basis of

Types

Evaporative Dry Eye Syndrome
Aqueous Dry Eye Syndrome

Treatments

Cyclosporine
Corticosteroids
Artificial Tears
Punctual Bags

Distribution Channels

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Novartis AG (Alcon)
ALLERGAN
Johnson & Johnson Vision Care, Inc.
Otsuka Pharmaceutical Vo. Ltd.
Shire plc
OASIS Medical
Santen Pharmaceutical Co. Ltd.
AFT Pharmaceuticals
I-Med Pharma Inc.
Novaliq GmbH
Sentiss Pharma Pvt. Ltd.
Scope Ophthalmics Ltd.

Competitive Landscape

Key players competing in the dry eye syndrome treatment market include Novartis AG (Alcon); ALLERGAN; Johnson & Johnson Vision Care, Inc.; Otsuka Pharmaceutical Vo. Ltd.; Shire plc; OASIS Medical; Santen Pharmaceutical Co. Ltd.; AFT Pharmaceuticals; I-Med Pharma Inc.; Novaliq GmbH; Sentiss Pharma Pvt. Ltd.; and Scope Ophthalmics Ltd.

Several strategies such as new product launch, technological development, mergers, and acquisitions are the adopted by these market players to expand their consumer base globally. For instance, Johnson & Johnson Vision Care, Inc. presented its program called New Data and Innovations in Eye Care at the British Contact Lens Association Conference (BCLA), which was held in the UK from 30th of May to the 1st of June, 2019.

Dry Eye Syndrome Treatment Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Dry Eye Syndrome Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Dry Eye Syndrome Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Dry Eye Syndrome Treatment Market - Supply Chain
  4.5. Global Dry Eye Syndrome Treatment Market Forecast
     4.5.1. Dry Eye Syndrome Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Dry Eye Syndrome Treatment Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Dry Eye Syndrome Treatment Market Absolute $ Opportunity
5. Global Dry Eye Syndrome Treatment Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Dry Eye Syndrome Treatment Market Size and Volume Forecast by Types
     5.3.1. Evaporative Dry Eye Syndrome
     5.3.2. Aqueous Dry Eye Syndrome
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Dry Eye Syndrome Treatment Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Dry Eye Syndrome Treatment Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Dry Eye Syndrome Treatment Demand Share Forecast, 2019-2026
7. North America Dry Eye Syndrome Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Dry Eye Syndrome Treatment Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Dry Eye Syndrome Treatment Market Size and Volume Forecast by Types
     7.4.1. Evaporative Dry Eye Syndrome
     7.4.2. Aqueous Dry Eye Syndrome
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Dry Eye Syndrome Treatment Demand Share Forecast, 2019-2026
8. Latin America Dry Eye Syndrome Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Dry Eye Syndrome Treatment Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Dry Eye Syndrome Treatment Market Size and Volume Forecast by Types
     8.4.1. Evaporative Dry Eye Syndrome
     8.4.2. Aqueous Dry Eye Syndrome
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Dry Eye Syndrome Treatment Demand Share Forecast, 2019-2026
9. Europe Dry Eye Syndrome Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Dry Eye Syndrome Treatment Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Dry Eye Syndrome Treatment Market Size and Volume Forecast by Types
     9.4.1. Evaporative Dry Eye Syndrome
     9.4.2. Aqueous Dry Eye Syndrome
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Dry Eye Syndrome Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Dry Eye Syndrome Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Dry Eye Syndrome Treatment Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Dry Eye Syndrome Treatment Market Size and Volume Forecast by Types
     10.4.1. Evaporative Dry Eye Syndrome
     10.4.2. Aqueous Dry Eye Syndrome
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Dry Eye Syndrome Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Dry Eye Syndrome Treatment Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Dry Eye Syndrome Treatment Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Dry Eye Syndrome Treatment Market Size and Volume Forecast by Types
     11.4.1. Evaporative Dry Eye Syndrome
     11.4.2. Aqueous Dry Eye Syndrome
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Dry Eye Syndrome Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Dry Eye Syndrome Treatment Market: Market Share Analysis
  12.2. Dry Eye Syndrome Treatment Distributors and Customers
  12.3. Dry Eye Syndrome Treatment Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Novartis AG (Alcon)
     12.4.2. ALLERGAN
     12.4.3. Johnson & Johnson Vision Care, Inc.
     12.4.4. Otsuka Pharmaceutical Vo. Ltd.
     12.4.5. Shire plc
     12.4.6. OASIS Medical
     12.4.7. Santen Pharmaceutical Co. Ltd.
     12.4.8. AFT Pharmaceuticals
     12.4.9. I-Med Pharma Inc.
     12.4.10. Novaliq GmbH